Schrödinger Inc (NASDAQ:SDGR) presented new preclinical data from its Wee1 inhibitor program at the American Association of Cancer Research (AACR) Annual Meeting.
- The data show that Schrödinger's Wee1 inhibitors have therapeutic potential for use as monotherapy and as part of combination therapy with other agents.
- Schrödinger is on track to select a Wee1 development candidate later this year.
- Subject to completing the preclinical data packages, Schrödinger anticipates submitting an FDA Investigation New Drug (IND) Application in 2023.
- A representative compound, STC-8123, was well tolerated in multiple preclinical models and demonstrated sustained pharmacodynamic and pharmacokinetic properties.
- The anti-tumor effects of STC-8123 were maintained during dosing holidays while allowing full recovery of mechanism-based hematological effects.
- Price Action: SDGR shares are up 2.47% at $31.95 during the market session on the last check Tuesday.
